[go: up one dir, main page]

AR057155A1 - Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina - Google Patents

Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina

Info

Publication number
AR057155A1
AR057155A1 ARP060104474A ARP060104474A AR057155A1 AR 057155 A1 AR057155 A1 AR 057155A1 AR P060104474 A ARP060104474 A AR P060104474A AR P060104474 A ARP060104474 A AR P060104474A AR 057155 A1 AR057155 A1 AR 057155A1
Authority
AR
Argentina
Prior art keywords
chlorophenil
benzodiazepina
pirazolo
metoxi
dihidro
Prior art date
Application number
ARP060104474A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37496611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057155A1 publication Critical patent/AR057155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere al uso del compuesto de la formula (1), para la fabricacion de medicamentos destinados al tratamiento del cáncer, dichos medicamentos se caracterizan porque aportan el compuesto anterior en una cantidad comprendida entre aproximadamente 1,5mg/m2/día y aproximadamente 30 mg/m2/día; así como a los métodos para tratar el cáncer mediante la administracion de dichos medicamentos.
ARP060104474A 2005-10-14 2006-10-12 Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina AR057155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72702005P 2005-10-14 2005-10-14

Publications (1)

Publication Number Publication Date
AR057155A1 true AR057155A1 (es) 2007-11-21

Family

ID=37496611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104474A AR057155A1 (es) 2005-10-14 2006-10-12 Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina

Country Status (12)

Country Link
US (1) US20070088023A1 (es)
EP (1) EP1940410A1 (es)
JP (1) JP2009511535A (es)
KR (2) KR20080055914A (es)
CN (1) CN101287469A (es)
AR (1) AR057155A1 (es)
AU (1) AU2006301292A1 (es)
BR (1) BRPI0617252A2 (es)
CA (1) CA2624025A1 (es)
IL (1) IL190339A0 (es)
TW (1) TW200727904A (es)
WO (1) WO2007042430A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
RU2640904C2 (ru) * 2012-08-20 2018-01-12 РАВАЛ Эй.Си.Эс. ЛТД. Вспомогательное устройство топливной системы транспортного средства
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681341A (en) * 1970-12-23 1972-08-01 Hoffmann La Roche Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5631156A (en) * 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6777534B1 (en) * 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US6413513B1 (en) * 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6774211B1 (en) * 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6783953B1 (en) * 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
ES2308551T3 (es) * 2004-10-13 2008-12-01 F. Hoffmann-La Roche Ag Pirazolobenzodiazepinas disustituidas utiles como inhibidores para cdk2 y angiogenesis, y para el tratamiento de cancer de mama, colon, pulmon y prostata.

Also Published As

Publication number Publication date
IL190339A0 (en) 2009-09-22
KR20110010813A (ko) 2011-02-07
CA2624025A1 (en) 2007-04-19
EP1940410A1 (en) 2008-07-09
WO2007042430A1 (en) 2007-04-19
TW200727904A (en) 2007-08-01
JP2009511535A (ja) 2009-03-19
KR20080055914A (ko) 2008-06-19
CN101287469A (zh) 2008-10-15
AU2006301292A1 (en) 2007-04-19
BRPI0617252A2 (pt) 2011-07-19
US20070088023A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
MX2010001574A (es) Ligandos del receptor cannabinoide.
UY28271A1 (es) Compuestos químicos
MX2009013501A (es) Compuestos piperidinicos y sus usos.
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR057155A1 (es) Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
WO2008051527A3 (en) Sustained release of agents for localized pain management

Legal Events

Date Code Title Description
FA Abandonment or withdrawal